Drug news
EMA finds MabThera (Genentech/Roche) safe to use.
The EMA has cleared MabThera (rituximab), from Genentech/Roche, as safe after an assessment found that contamination at the manufacturer's bioreactors poses little threat. This follows a contamination scare at Roche's facility in Vacaville, California, US. MabThera is approved to treat Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia, as well as Rheumatoid Arthritis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.